HyperkalemiaMANAGEMENT

ENDOCRINE AND METABOLIC PRESENTATIONS · 12 SECTIONS

⚲

798 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

Acute Porphyria Adrenal crisis Adrenal Insufficiency (Addisonian Crisis)Dehydration Diabetes Insipidus Diabetic Ketoacidosis (DKA)Euglycemic DKA (SGLT2 inhibitor)Galactosemia GLP-1 receptor agonist complications (retained gastric contents, aspiration risk)Homocystinuria Hypercalcemia Hyperkalemia Hypermagnesemia Hypernatremia Hyperosmolar Hyperglycemic State (HHS)Hypertensive emergency Hypertensive urgency Hypocalcemia Hypoglycemia Hypogonadism (Acute Presentation)Hypokalemia Hypomagnesemia Hyponatremia Hypoparathyroidism (Tetany)Insulin pump failure Maple Syrup Urine Disease (Crisis)Medium-Chain Acyl-CoA Dehydrogenase Deficiency (MCAD)Metabolic Acidosis Metabolic Alkalosis Myasthenia gravis crisis Myxedema coma Pellagra Pheochromocytoma (Crisis)Pituitary Apoplexy Pompe Disease (GSD II)Respiratory Acidosis Respiratory Alkalosis Scurvy SIADH Starvation Ketosis Tarui Disease (GSD VII)Thyroid storm Tyrosinemia Vitamin D Deficiency (Severe-Rickets)Von Gierke Disease (GSD I)

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp63

Immediate resuscitation priorities

›Airway and breathing threats

›Respiratory muscle weakness in severe hyperkalemia

›Ascending paralysis reaching diaphragm

›SpO2 decline with progressive weakness

›If unable to protect airway, prepare for definitive airway

›Avoid succinylcholine — risk of fatal potassium surge

›Use rocuronium as alternative neuromuscular blockade

›Oxygenation targets

›SpO2 >= 94%

›Supplemental oxygen titrated to target

›Cardiac arrest and arrhythmia threats

›Immediate 12-lead ECG on arrival

›Peaked T waves earliest sign

›QRS widening high-risk sign

›Sine wave pattern pre-arrest pattern

›Cardiac arrest rhythms in hyperkalemia

›VF

›VT

›PEA

›Asystole

›If arrest: calcium chloride 10% 10 mL IV push before ACLS

›2025 AHA Guidelines recommendation

›Repeat every 5 minutes as needed during resuscitation

›Hemodynamic stability assessment

›Bradycardia as ominous clinical sign

›Relative risk 12.3 for serious adverse event within 6 hours

›Junctional rhythm relative risk 7.5

02History/hx89

Symptom characterization

›Cardinal neuromuscular symptoms

›Muscle weakness

›Proximal distribution

›Ascending pattern

›Paresthesias

›Tingling or numbness in extremities

›Perioral tingling

›Fatigue

›Generalized

›Worsening with activity

›Cardiac symptoms

›Palpitations

›Irregular heartbeat sensation

›Slow heart rate awareness

›Presyncope or syncope

›Positional component

›Preceding weakness

›Chest pain or pressure

›GI symptoms

›Nausea and vomiting

›Abdominal pain

›Ileus pattern

›Distension

›Diarrhea

›Renal symptoms

›Decreased urine output

›Oliguria suggesting renal failure

03Physical Exam/exam67

Vital signs and general

›Hemodynamic snapshot

›Heart rate

›Bradycardia as ominous sign of advanced toxicity

›Irregular rhythm suggesting arrhythmia

›Blood pressure

›Hypotension in severe cases

›SBP < 90 mmHg triggers ICU escalation

›Respiratory rate

›Tachypnea with respiratory muscle compromise

›Decreased effort with paralysis

›Oxygen saturation

›Decline with diaphragmatic weakness

›General appearance

›Level of consciousness

›Altered mental status in severe cases

›Degree of distress

›Dyspneic appearance

›Weakness visible on observation

Neuromuscular exam

›Motor assessment

›Proximal limb weakness

›Difficulty rising from chair

›Hip flexor testing

›Ascending paralysis pattern

›Legs before arms

›Respiratory muscles last

›Flaccid paralysis in severe cases

04Differential Diagnosis/ddx60

Life-threatening causes

›Renal failure

›Acute kidney injury

›ICD-10 N17.9

›Rapid rise in creatinine and K+

›ESRD with missed dialysis

›ICD-10 N18.6

›Most common severe hyperkalemia context

›Acute adrenal crisis

›Addison's disease

›ICD-10 E27.1

›Hyponatremia co-occurring

›Type IV renal tubular acidosis

›Hyporeninemic hypoaldosteronism

›Diabetes mellitus association

›Massive tissue release

›Rhabdomyolysis

›ICD-10 M62.82

›CK elevation >10,000 U/L

›Tumor lysis syndrome

›ICD-10 E88.3

›Hyperuricemia and hyperphosphatemia co-occurring

›Massive hemolysis

›Transfusion reaction

›G6PD deficiency trigger

Medication-induced

›RAAS inhibitor-induced

›ACE inhibitor effect

05Laboratory Tests/lt69

Serum electrolytes

›Serum potassium

›Mild hyperkalemia: 5.0-5.9 mmol/l

›Often asymptomatic

›Identifiable cause usually present

›Moderate hyperkalemia: 6.0-6.4 mmol/l

›Increasing cardiac risk

›Mandatory ECG

›Severe hyperkalemia: >= 6.5 mmol/l

›Life-threatening arrhythmia risk

›Immediate treatment required

›Redraw without tourniquet if value unexpected or discordant with symptoms

›Sodium

›Hyponatremia co-occurring with adrenal insufficiency

›Hypernatremia with volume depletion

›Bicarbonate

›Acidosis lowers pH 0.1 unit raises K+ 0.4-0.6 mmol/l

›Low bicarbonate guides sodium bicarbonate therapy indication

›Calcium and magnesium

›Hypocalcemia worsens cardiac toxicity

›Hypomagnesemia promotes arrhythmia

›Phosphorus

›Hyperphosphatemia in tumor lysis and renal failure

Renal function

›BUN and creatinine

›Acute vs chronic renal failure distinction

›Prior baseline creatinine comparison

›Rate of rise

06Diagnostic Tests/dt58

Scoring Systems

›Hyperkalemia severity classification

›Mild: K+ 5.0-5.9 mmol/l, no ECG changes

›Management: dietary restriction, medication review

›Moderate: K+ 6.0-6.4 mmol/l

›Management: intracellular shift + elimination

›Severe: K+ >= 6.5 mmol/l or any ECG change

›Management: full three-tier emergency protocol

›Cairo-Bishop tumor lysis syndrome criteria

›Laboratory TLS: 2+ abnormalities within 3 days of treatment

›Uric acid > 0.48 mmol/l or 25% rise

›K+ > 6.0 mmol/l or 25% rise

›Phosphorus > 2.1 mmol/l or 25% rise

›Calcium < 1.75 mmol/l or 25% fall

›Clinical TLS: laboratory TLS plus organ dysfunction

›ECG progression scoring (Mitchell-Brady framework)

›Stage 1: Peaked T waves (K+ 5.5-6.5 mmol/l)

›Narrow base, amplitude > R wave in V5

›Stage 2: PR prolongation and P wave flattening (K+ 6.5-7.0 mmol/l)

›Stage 3: QRS widening (K+ 7.0-8.0 mmol/l)

›QRS > 120 ms

›Stage 4: Sine wave, VT, VF, asystole (K+ > 8.0 mmol/l)

MRI

›MRI utility in hyperkalemia

›Not routinely indicated for hyperkalemia diagnosis

›Role limited to evaluation of complications

›Spinal cord MRI if ascending paralysis is atypical

›Exclude cord compression or transverse myelitis

07Disposition/dispo48

Admission criteria

›ICU or continuous monitoring level

›K+ >= 6.5 mmol/l with any ECG changes

›Telemetry mandatory until resolution

›Hemodynamic instability

›Bradycardia or hypotension from hyperkalemia

›Respiratory muscle compromise

›Rising PaCO2 or declining SpO2

›Requiring emergent hemodialysis

›Renal consult initiated from ED

›Cardiac arrest from hyperkalemia

›ICU post-resuscitation care

›Telemetry floor admission

›K+ >= 6.5 mmol/l without ECG changes

›Monitor for development of ECG findings

›Symptomatic hyperkalemia (K+ >= 6.0 mmol/l)

›Weakness or palpitations

›Insulin-glucose therapy administered

›Minimum 4-6 hours glucose monitoring required

›Ongoing potassium source (rhabdomyolysis, TLS)

›Serial K+ monitoring required

›Significant renal failure without established dialysis access

Observation

›Observation candidates (4-8 hours)

›K+ 6.0-6.4 mmol/l without ECG changes

›Repeat K+ 1-2 hours after treatment

›Discharge if K+ < 5.5 mmol/l and clinically stable

›Patients requiring insulin-glucose monitoring

08Treatment/t91

Tier 1 — Cardiac membrane stabilization

›Calcium gluconate 10%

›Indication: ECG changes or K+ >= 6.5 mmol/l

›Do not wait for repeat lab — treat ECG changes immediately

›Dose: 1,000-2,000 mg (10-20 mL) IV over 2-5 minutes

›Onset: 1-3 minutes

›Duration: 30-60 minutes

›If ECG changes persist, repeat in 5-10 minutes

›Mechanism: raises threshold potential, does not lower K+

›Calcium chloride 10%

›Indication: cardiac arrest or severe hemodynamic instability

›Contains 3x more elemental calcium than gluconate

›2025 AHA Guidelines recommendation

›Dose: 10 mL IV push in cardiac arrest

›Repeat every 5 minutes during resuscitation

›Requires central line ideally — vesicant if extravasated peripherally

›Digoxin caution

›Administer over 20-30 minutes if patient is digitalized

›Calcium exacerbates digoxin-induced arrhythmias

›Avoid mixing calcium with sodium bicarbonate in same IV line

›Calcium-bicarbonate precipitation occurs

›Flush line between administrations

Tier 2 — Intracellular potassium shift

›Regular insulin with dextrose

›Dose: Regular insulin 10 units IV + dextrose 25 g (D50 50 mL) IV

›Lowers K+ by 0.6-1.2 mmol/l within 1 hour

›Effect begins in 15-30 minutes

›If glucose > 13.9 mmol/l (250 mg/dL): give insulin without dextrose

›If glucose < 5.5 mmol/l (100 mg/dL): give additional dextrose before insulin

›Post-treatment glucose monitoring

›Q1h for minimum 4-6 hours

›Hypoglycemia most common complication — especially in non-diabetic patients

›Treat hypoglycemia with D50 25-50 mL IV bolus

›Nebulized albuterol (salbutamol)

›Dose: 10-20 mg nebulized over 10 minutes

›Lowers K+ by approximately 0.6 mmol/l within 30 minutes

›Synergistic with insulin-glucose — combined effect 1.2-1.5 mmol/l reduction

›Mechanism: beta-2 agonist stimulates Na-K-ATPase

›Effect lasts 2-4 hours

›Caution in ischemic heart disease

›Tachycardia side effect

›Approximately 40% of patients are non-responders

›Sodium bicarbonate

›Indication: concurrent metabolic acidosis (pH < 7.2, bicarbonate < 15 mmol/l)

›Not effective as monotherapy for hyperkalemia without acidosis

›Avoid in ESRD due to volume load risk

›Dose: 150 mEq in 1L D5W over 2-4 hours

›Do not use normal saline as diluent

›Do not mix with calcium in same line

Tier 3 — Potassium elimination

›Loop diuretics

›Furosemide

›Indication: adequate renal function (GFR > 30 mL/min) and urine output

›Dose: 40-80 mg IV

›Ineffective in oliguric or anuric patients

›Sodium zirconium cyclosilicate (Lokelma)

›Acute indication: K+ >= 5.0 mmol/l requiring outpatient or non-urgent inpatient management

›Dose: 10 g PO TID for 48 hours (acute phase)

›Maintenance: 5-10 g PO once daily

›Onset: 1-2 hours (faster than patiromer)

›Mechanism: zirconium lattice traps K+ in GI tract

›Can be given in dialysis patients

›Patiromer (Veltassa)

›Dose: 8.4 g PO daily

›Titrate to 16.8-25.2 g/day as needed

›Better suited for chronic management than acute

›Onset: 7 hours — not for immediate emergency use

›Must be separated from other medications by 3 hours

›Adsorbs other drugs

›Sodium polystyrene sulfonate (Kayexalate)

›No longer recommended for acute management

›Questionable efficacy for K+ lowering

›Risk of GI adverse events including intestinal necrosis

›Cochrane review 2015 supports this position

›Hemodialysis

›Definitive treatment for refractory hyperkalemia

›Removes 25-50 mmol/l per session

›Onset immediate once initiated

›Indications

›ESRD with K+ >= 6.5 mmol/l

›Oliguric or anuric AKI with ECG changes

›Failure to respond to medical management

›Ongoing potassium release source (rhabdomyolysis, TLS)

›Peritoneal dialysis

›Less efficient than hemodialysis for acute hyperkalemia

›Use only if HD unavailable

Potassium elimination — avoidance measures

›Immediate potassium source restriction

›Hold all potassium-containing IV fluids

›Replace lactated Ringer's with normal saline

›Eliminate potassium supplements and salt substitutes

›Nil by mouth or low-potassium diet order

›Review and hold causative medications

›ACEi, ARBs, potassium-sparing diuretics, NSAIDs

›Reassess risk-benefit before restarting

09Special Populations/sp97

Pregnancy

›Physiologic considerations

›Normal serum K+ in pregnancy

›Slight decrease due to increased GFR and aldosterone

›Normal range 3.5-4.5 mmol/l

›Pre-eclampsia and HELLP syndrome

›AKI in HELLP can cause hyperkalemia

›Magnesium therapy co-administration common

›Treatment modifications

›Calcium gluconate

›Safe in pregnancy for membrane stabilization

›Also used for magnesium toxicity reversal

›Insulin-dextrose

›Safe and effective in pregnancy

›Monitor for fetal effects of maternal hypoglycemia

›Albuterol

›Generally considered safe in pregnancy

›Tocolytic effect — monitor for uterine relaxation

›Sodium zirconium cyclosilicate

›Limited data in pregnancy — use only if essential

›Patiromer

›Avoid in pregnancy — insufficient safety data

›Hemodialysis in pregnancy

›More frequent and longer sessions required

›Maternal and fetal outcome data limited

›Delivery considerations

›Hyperkalemia as cause of fetal arrhythmia

›Fetal monitoring intensification

›Postpartum acute kidney injury risk

Geriatric

›Increased susceptibility

›Reduced renal reserve

›GFR declines approximately 1 mL/min/year after age 40

›Reduced tubular K+ secretion

›Polypharmacy burden

›Higher rate of RAAS inhibitor and NSAID use

›Drug-drug interactions increasing risk

›Reduced aldosterone response

›Type IV RTA more prevalent

›Atypical presentation

›Weakness may be attributed to frailty or deconditioning

›Low threshold for ECG and electrolyte testing

›Constipation common

›Impairs colonic K+ excretion

›Dehydration more frequent

›Reduces renal K+ excretion

›Treatment considerations

›Calcium gluconate

›Venous access may be difficult — consider central access

›Insulin-glucose

›Higher hypoglycemia risk in elderly

›Reduce insulin dose to 5 units if concerns

›Extended glucose monitoring (6+ hours)

›Albuterol

›Higher rate of tachycardia and arrhythmia

›Use with caution in known coronary artery disease

›Sodium zirconium cyclosilicate or patiromer

›Preferred over SPS for chronic management

›Enable continued RAAS inhibitor therapy in heart failure and CKD

›Dialysis considerations

›Increased risk of hemodynamic instability during HD

›Slower fluid removal rates may be required

Pediatrics

›Age-specific normal values

›Hyperkalemia threshold in children > 5.5 mmol/l

›Neonates tolerate 5.5-6.5 mmol/l if well

›Preterm neonates at higher risk from immaturity of Na-K-ATPase

›Nonoliguric hyperkalemia of prematurity

›Occurs in first 72 hours of life

›ECG monitoring mandatory

›Common pediatric causes

›Pseudohyperkalemia most common in neonates

›Heel stick hemolysis

›Confirm with free-flowing venous sample

›Congenital adrenal hyperplasia

›Salt-wasting form in neonates

›Ambiguous genitalia clue in females

›Obstructive uropathy

›Posterior urethral valves in males

›Tumor lysis syndrome in pediatric malignancy

›Weight-based treatment dosing

›Calcium gluconate 10%

›Dose: 60-100 mg/kg (0.6-1.0 mL/kg) IV over 5-10 minutes

›Maximum single dose: 3,000 mg

›Cardiac monitoring during infusion

›Regular insulin

›Dose: 0.1 units/kg IV (maximum 10 units)

›Dextrose: 0.5 g/kg (2 mL/kg D25 or 5 mL/kg D10)

›Glucose monitoring Q30min for 2 hours then Q1h

›Albuterol nebulized

›Dose: 2.5 mg for < 25 kg, 5 mg for >= 25 kg

›May need to repeat after 20 minutes

›Sodium bicarbonate

›Dose: 1-2 mEq/kg IV if pH < 7.2

›Kayexalate

›Contraindicated in neonates and post-operative bowel states

›Risk of intestinal necrosis highest in premature infants

›Hemodialysis in children

›Peritoneal dialysis often preferred for infants

›Pediatric nephrology consultation essential

10Background/b87

Epidemiology

›Prevalence

›General population prevalence approximately 3.3%

›Rising to 18% in patients with CKD

›50% prevalence in ESRD patients on dialysis

›Hospital setting prevalence

›1-10% of hospitalized patients

›Higher in ICU settings

›Mortality and morbidity

›U-shaped relationship between K+ and mortality

›Optimal serum K+ 4.0-5.0 mmol/l

›Both hypokalemia and hyperkalemia increase mortality

›Fatal arrhythmia risk increases sharply at K+ > 6.5 mmol/l

›VF and asystole primary lethal mechanisms

›In-hospital mortality for severe hyperkalemia

›Significantly increased when ECG changes present

›High-risk populations

›CKD stage 3-5: 18-44% prevalence

›Heart failure with RAAS inhibitor use: 19-37% prevalence

›Diabetes mellitus: increased risk from hyporeninemic hypoaldosteronism

›ICD-10 coding

›Hyperkalemia: E87.5

›Disorder of potassium balance: E87.5

Pathophysiology

›Normal potassium homeostasis

›Total body potassium 3,500 mmol (98% intracellular)

›ICF K+ approximately 140 mmol/l

›ECF K+ 3.5-5.0 mmol/l

›Renal excretion accounts for 90-95% of daily K+ elimination

›Principal cells of cortical collecting duct primary site

›Aldosterone drives K+ secretion via ROMK channels

›Colonic K+ secretion accounts for 5-10%

›Increases adaptively in CKD

›Mechanisms of hyperkalemia

›Reduced renal excretion

›GFR < 15 mL/min/1.73m2 critically impairs excretion

›Aldosterone deficiency or resistance

›Type IV RTA (hyporeninemic hypoaldosteronism)

›Transcellular shift (extracellular redistribution)

›Acidosis: pH decrease 0.1 raises K+ 0.4-0.6 mmol/l

›Insulin deficiency

›Beta-blockade reducing cellular uptake

›Hyperosmolality (hyperglycemia)

›Excess potassium load

›Dietary intake in setting of reduced excretion

›Endogenous release: rhabdomyolysis, hemolysis, TLS

›Exogenous: supplements, salt substitutes, blood products

›Cardiac toxicity mechanism

›Hyperkalemia depolarizes resting membrane potential

›Reduces gap between resting potential and threshold

›Results in reduced cardiac excitability paradoxically

›Slows conduction velocity

›QRS prolongation and arrhythmia

›Rate of K+ rise matters as much as absolute level

›Patients with chronically elevated K+ may have partial adaptation

Therapeutic Considerations

›Rationale for three-tier approach

›Tier 1 protects the heart but does not lower K+

›Calcium buys 30-60 minutes only

›All three tiers must be initiated simultaneously in severe cases

›Tier 2 provides temporary shift — not elimination

›Without Tier 3, K+ will rebound within 4-6 hours

›Shift therapies critical for time while elimination begins

›Tier 3 is the only definitive treatment

›Renal excretion preferred when feasible

›Dialysis for oliguric-anuric patients

›Newer potassium binders vs SPS

›Sodium zirconium cyclosilicate (Lokelma)

›FDA approved 2018

›Phase III HARMONIZE trial: K+ lowering in 48 hours

›Faster onset than patiromer (1-2 hours vs 7 hours)

›Patiromer

›FDA approved 2015

›OPAL-HK trial: enabled continued RAAS inhibitor therapy in CKD-HF

›Better suited for chronic management

›Both preferred over SPS due to safety and efficacy profile

›RAAS inhibitor continuation debate

›Discontinuing RAAS inhibitors trades reduced hyperkalemia for increased CV and renal risk

›RAAS inhibitors provide mortality benefit in HF and diabetic CKD

›KDIGO 2024 guideline: use potassium binders to maintain RAAS inhibitors

›Dietary modification enables RAAS inhibitor continuation in many cases

›Reduction in nonplant potassium sources more impactful than blanket restriction

›Plant-based K+ lower bioavailability

›Monitoring strategy after treatment

›Shift therapies (insulin, albuterol): effect begins 15-30 min, peaks 60 min

›Repeat K+ at 1-2 hours

›Elimination therapies: effect over hours

›Repeat K+ at 4-6 hours

›Rebound hyperkalemia common if source not eliminated

›Serial K+ every 4-6 hours until stable

11Patient Discharge Instructions/pdi32

copy discharge instructions

›Discharge instructions for Hyperkalemia

›Your potassium level was found to be too high (hyperkalemia). High potassium can be dangerous for your heart and muscles. You have been treated and your potassium level is now in a safer range. It is important to follow these instructions carefully to prevent it from rising again.

›Medications

›Take all medications exactly as prescribed

›Do NOT restart the following medications until cleared by your doctor

›Any ACE inhibitor or ARB blood pressure medications (if held)

›Any potassium-sparing water pills (spironolactone, amiloride)

›Potassium supplements

›Avoid anti-inflammatory medications (ibuprofen, naproxen, NSAIDs) unless prescribed

›Check with your pharmacist about any over-the-counter medications

›Diet

›Limit high-potassium foods

›Avoid: bananas, oranges, tomatoes, potatoes, avocados, spinach

›Avoid: salt substitutes and No Salt products (contain potassium chloride)

›Avoid: herbal supplements including alfalfa, dandelion, and nettle

›Stay well hydrated unless you have been told to restrict fluids

›Avoid constipation — ask your doctor about stool softeners if needed

›If you have kidney disease, ask to see a kidney dietitian for a personalized plan

›Dialysis

›Do NOT miss any scheduled dialysis sessions

›If you are unable to attend dialysis, call your dialysis centre immediately

›Follow-up

›Recheck blood potassium within 24-72 hours as arranged

›Attend all scheduled follow-up appointments

›Return to the Emergency Department immediately if you develop

›Muscle weakness that is getting worse, especially in your legs or arms

›Difficulty breathing

12References/r37

Guidelines and key sources

›2025 AHA Guidelines for CPR and Emergency Cardiovascular Care

›Cao D, Arens AM, Chow SL, et al. Part 10: Adult and Pediatric Special Circumstances of Resuscitation. Circulation. 2025.

›Recommends calcium chloride in hyperkalemic cardiac arrest

›Three-tier treatment framework endorsed

›American Family Physician Potassium Disorders Review 2023

›Kim MJ, Valerio C, Knobloch GK. Potassium Disorders: Hypokalemia and Hyperkalemia. AAFP. 2023.

›Comprehensive outpatient and inpatient management framework

›Cochrane Review: Pharmacological Interventions for Acute Hyperkalaemia 2015

›Batterink J, Cessford TA, Taylor RA. Cochrane Database Syst Rev. 2015.

›SPS efficacy questioned; insulin-glucose and albuterol supported

›KDIGO 2024 Clinical Practice Guideline for Evaluation and Management of CKD

›Kidney International. 2024.

›Recommends potassium binders to enable RAAS inhibitor continuation

›VA/DoD Primary Care Management of CKD Guideline 2025

›Brown JC et al. Department of Veterans Affairs. 2025.

›Sodium zirconium cyclosilicate and patiromer recommendations

›Hyperkalemia Treatment Standard 2024

›Palmer BF, Clegg DJ. Nephrol Dial Transplant. 2024.

›Three-tier treatment rationale and evidence basis

›Acute Hyperkalaemia in Emergency Care 2026

›Geldermann N, Dzimiera J, Fischer H, Christ M. Emerg Med J. 2026.

›Emergency department evidence-based approaches

›Hyperkalemia: Pathophysiology, Risk Factors and Consequences 2019

›Hunter RW, Bailey MA. Nephrol Dial Transplant. 2019.

›Epidemiology and mechanistic basis

›ECG in Hyperkalemia 2023

›Mitchell SH, Brady WJ. In: The Electrocardiogram in Emergency and Acute Care. 2023.

Learn More: Hyperkalemia→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.